2015
DOI: 10.1016/j.clinthera.2014.12.008
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of Montelukast, Doxofylline, and Tiotropium With Budesonide for the Treatment of Asthma: Which Is the Best Among the Second-line Treatment? A Randomized Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
21
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(22 citation statements)
references
References 19 publications
1
21
0
Order By: Relevance
“…The study of Rajanandh and coworkers aimed to compare the 6 month efficacy and safety of formoterol (12 mcg), montelukast (10 mg), doxofylline (400 mg), or tiotropium (18 mcg) in combination with a low-dose budesonide (400 mcg) in patients with mild to moderate persistent asthma [ 27 ]. Outcomes included FEV1, Saint George Respiratory Questionnaire (SGRQ) scores, asthma symptom scores (daytime and night time), assessment of tolerability and rescue medication use.…”
Section: Resultsmentioning
confidence: 99%
“…The study of Rajanandh and coworkers aimed to compare the 6 month efficacy and safety of formoterol (12 mcg), montelukast (10 mg), doxofylline (400 mg), or tiotropium (18 mcg) in combination with a low-dose budesonide (400 mcg) in patients with mild to moderate persistent asthma [ 27 ]. Outcomes included FEV1, Saint George Respiratory Questionnaire (SGRQ) scores, asthma symptom scores (daytime and night time), assessment of tolerability and rescue medication use.…”
Section: Resultsmentioning
confidence: 99%
“…These cells release mediators such as chemokine, cysteinyl leukotrienes, cytokines, histamine, nitric oxide and prostaglandin D-2 (PGD 2 ), which contribute to the symptoms of asthma. Inflammatory mediators were also produced by structural cells of the airways and they contribute to the perseverance of inflammation in other ways (Rajanandh et al, 2015).…”
Section: Pathophysiologymentioning
confidence: 99%
“…The p38 MAP kinase inhibitors such as SB203580 and RWJ67657 inhibit the synthesis of many inflammatory cytokines and chemokines and therefore, they are in the process of development for the treatment of asthma and COPD (Rajanandh et al, 2015).…”
Section: Newer Anti-inflammatory Drugsmentioning
confidence: 99%
“…The objectives of the asthma treatment are not fulfilled completely with only inhaled corticosteroid (ICS). For this reason, without increasing the dose of ICS, the addition of a second drug with complementary mechanism is preferred [3][4][5].…”
Section: Introductionmentioning
confidence: 99%